MedTrace Logo

EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease

NCT00531011 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-06-08

Study results available
· View outcomes & findings →

Summary

The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary Artery Disease (MVD).

Conditions

Interventions

DEVICE

XIENCE V® Everolimus Eluting Coronary Stent System

Coronary artery placement of a drug-eluting stent

DEVICE

TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System

Coronary artery placement of a drug-eluting stent

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Corrado Vassanelli, MD · Ospedale Civile Maggiore - Università di Verona

  • Flavio Ribichini, MD · Ospedale Civile Maggiore - Università di Verona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-03-31
Completion
2011-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00531011 on ClinicalTrials.gov